Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,483
archived clinical trials in
Influenza

A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status: Enrolling
Updated:  1/31/2013
Clinical Research Facility
mi
from
Helena, MT
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status: Enrolling
Updated: 1/31/2013
Clinical Research Facility
mi
from
Helena, MT
Click here to add this to my saved trials
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status: Enrolling
Updated:  1/31/2013
Clinical Research Facility
mi
from
Omaha, NE
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status: Enrolling
Updated: 1/31/2013
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status: Enrolling
Updated:  1/31/2013
Clinical Research Facility
mi
from
Newark, NJ
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status: Enrolling
Updated: 1/31/2013
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status: Enrolling
Updated:  1/31/2013
Clinical Research Facility
mi
from
New York, NY
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status: Enrolling
Updated: 1/31/2013
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status: Enrolling
Updated:  1/31/2013
Clinical Research Facility
mi
from
Ashville, NC
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status: Enrolling
Updated: 1/31/2013
Clinical Research Facility
mi
from
Ashville, NC
Click here to add this to my saved trials
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status: Enrolling
Updated:  1/31/2013
Clinical Research Facility
mi
from
Cleveland, OH
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status: Enrolling
Updated: 1/31/2013
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status: Enrolling
Updated:  1/31/2013
Clinical Research Facility
mi
from
Tulsa, OK
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status: Enrolling
Updated: 1/31/2013
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status: Enrolling
Updated:  1/31/2013
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status: Enrolling
Updated: 1/31/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status: Enrolling
Updated:  1/31/2013
Clinical Research Facility
mi
from
Dallas, TX
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status: Enrolling
Updated: 1/31/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status: Enrolling
Updated:  1/31/2013
Clinical Research Facility
mi
from
Norfolk, VA
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status: Enrolling
Updated: 1/31/2013
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status: Enrolling
Updated:  1/31/2013
Clinical Research Facility
mi
from
Huntington, WV
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status: Enrolling
Updated: 1/31/2013
Clinical Research Facility
mi
from
Huntington, WV
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults
A Phase II, Randomized, Observer-Blind With Single-Blind Booster, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects.
Status: Enrolling
Updated:  2/5/2013
Clinical Research Facility
mi
from
Daytona Beach, FL
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults
A Phase II, Randomized, Observer-Blind With Single-Blind Booster, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects.
Status: Enrolling
Updated: 2/5/2013
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults
A Phase II, Randomized, Observer-Blind With Single-Blind Booster, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects.
Status: Enrolling
Updated:  2/5/2013
Clinical Research Facility
mi
from
St. Joseph, MO
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults
A Phase II, Randomized, Observer-Blind With Single-Blind Booster, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects.
Status: Enrolling
Updated: 2/5/2013
Clinical Research Facility
mi
from
St. Joseph, MO
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults
A Phase II, Randomized, Observer-Blind With Single-Blind Booster, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects.
Status: Enrolling
Updated:  2/5/2013
Clinical Research Facility
mi
from
Dallas, TX
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults
A Phase II, Randomized, Observer-Blind With Single-Blind Booster, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects.
Status: Enrolling
Updated: 2/5/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Optimizing Influenza Vaccination in Surgical Oncology Patients
Optimizing Influenza Vaccination in Surgical Oncology Patients
Status: Enrolling
Updated:  4/18/2013
Stony Brook Hospital
mi
from
Stony Brook, NY
Optimizing Influenza Vaccination in Surgical Oncology Patients
Optimizing Influenza Vaccination in Surgical Oncology Patients
Status: Enrolling
Updated: 4/18/2013
Stony Brook Hospital
mi
from
Stony Brook, NY
Click here to add this to my saved trials
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
Status: Enrolling
Updated:  5/20/2013
Clinical Research Facility
mi
from
Fort Lauderdale, FL
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
Status: Enrolling
Updated: 5/20/2013
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
Status: Enrolling
Updated:  5/20/2013
Clinical Research Facility
mi
from
Atlanta, GA
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
Status: Enrolling
Updated: 5/20/2013
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
Status: Enrolling
Updated:  5/20/2013
Clinical Research Facility
mi
from
Bend, OR
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
Status: Enrolling
Updated: 5/20/2013
Clinical Research Facility
mi
from
Bend, OR
Click here to add this to my saved trials
TIV and High Dose TIV in Subjects With Rheumatoid Arthritis
A Phase II Study in Adults With Rheumatoid Arthritis Receiving TNF-alpha-inhibitor Therapy to Assess the Immunogenicity and Safety of Trivalent Inactivated Vaccine (TIV) and High Dose Trivalent Inactivated Vaccine (High-Dose TIV) Administered at Two Dosage Levels
Status: Enrolling
Updated:  5/30/2013
University of Iowa - Infectious Disease Clinic
mi
from
Iowa City, IA
TIV and High Dose TIV in Subjects With Rheumatoid Arthritis
A Phase II Study in Adults With Rheumatoid Arthritis Receiving TNF-alpha-inhibitor Therapy to Assess the Immunogenicity and Safety of Trivalent Inactivated Vaccine (TIV) and High Dose Trivalent Inactivated Vaccine (High-Dose TIV) Administered at Two Dosage Levels
Status: Enrolling
Updated: 5/30/2013
University of Iowa - Infectious Disease Clinic
mi
from
Iowa City, IA
Click here to add this to my saved trials
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated:  6/14/2013
Pfizer Investigational Site
mi
from
Gilbert, AZ
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated: 6/14/2013
Pfizer Investigational Site
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated:  6/14/2013
Pfizer Investigational Site
mi
from
Los Angeles, CA
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated: 6/14/2013
Pfizer Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated:  6/14/2013
Pfizer Investigational Site
mi
from
Arvada, CO
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated: 6/14/2013
Pfizer Investigational Site
mi
from
Arvada, CO
Click here to add this to my saved trials
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated:  6/14/2013
Pfizer Investigational Site
mi
from
Atlantis, FL
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated: 6/14/2013
Pfizer Investigational Site
mi
from
Atlantis, FL
Click here to add this to my saved trials
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated:  6/14/2013
Pfizer Investigational Site
mi
from
Boise, ID
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated: 6/14/2013
Pfizer Investigational Site
mi
from
Boise, ID
Click here to add this to my saved trials
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated:  6/14/2013
Pfizer Investigational Site
mi
from
Bloomingdale, IL
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated: 6/14/2013
Pfizer Investigational Site
mi
from
Bloomingdale, IL
Click here to add this to my saved trials
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated:  6/14/2013
Pfizer Investigational Site
mi
from
Bossier City, LA
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated: 6/14/2013
Pfizer Investigational Site
mi
from
Bossier City, LA
Click here to add this to my saved trials
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated:  6/14/2013
Pfizer Investigational Site
mi
from
Baltimore, MD
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated: 6/14/2013
Pfizer Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated:  6/14/2013
Pfizer Investigational Site
mi
from
Duluth, MN
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated: 6/14/2013
Pfizer Investigational Site
mi
from
Duluth, MN
Click here to add this to my saved trials
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated:  6/14/2013
Pfizer Investigational Site
mi
from
Cape Girardeau, MO
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated: 6/14/2013
Pfizer Investigational Site
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated:  6/14/2013
Pfizer Investigational Site
mi
from
Kalispell, MT
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated: 6/14/2013
Pfizer Investigational Site
mi
from
Kalispell, MT
Click here to add this to my saved trials
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated:  6/14/2013
Pfizer Investigational Site
mi
from
Rochester, NY
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated: 6/14/2013
Pfizer Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated:  6/14/2013
Pfizer Investigational Site
mi
from
Asheville, NC
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated: 6/14/2013
Pfizer Investigational Site
mi
from
Asheville, NC
Click here to add this to my saved trials
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated:  6/14/2013
Pfizer Investigational Site
mi
from
Akron, OH
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated: 6/14/2013
Pfizer Investigational Site
mi
from
Akron, OH
Click here to add this to my saved trials
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated:  6/14/2013
Pfizer Investigational Site
mi
from
Pittsburgh, PA
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated: 6/14/2013
Pfizer Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated:  6/14/2013
Pfizer Investigational Site
mi
from
Bristol, TN
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated: 6/14/2013
Pfizer Investigational Site
mi
from
Bristol, TN
Click here to add this to my saved trials
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated:  6/14/2013
Pfizer Investigational Site
mi
from
Houston, TX
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated: 6/14/2013
Pfizer Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated:  6/14/2013
Pfizer Investigational Site
mi
from
West Jordan, UT
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3, Randomized, Double Blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (TIV) In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vPnC Administered 5 Years After Initial 13vPnC Vaccination
Status: Enrolling
Updated: 6/14/2013
Pfizer Investigational Site
mi
from
West Jordan, UT
Click here to add this to my saved trials
Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CR6261, a Monoclonal Antibody Against Influenza A Viruses, Following Single-Dose Intravenous Administration
Status: Enrolling
Updated:  7/10/2013
Quintiles Early Clinical Development
mi
from
Overland Park, KA
Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CR6261, a Monoclonal Antibody Against Influenza A Viruses, Following Single-Dose Intravenous Administration
Status: Enrolling
Updated: 7/10/2013
Quintiles Early Clinical Development
mi
from
Overland Park, KA
Click here to add this to my saved trials
Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CR8020, a Monoclonal Antibody Against Influenza A Viruses, Following Single-Dose and Repeat-Dose Intravenous Administration
Status: Enrolling
Updated:  7/16/2013
Quintiles Early Clinical Development
mi
from
Overland Park, KA
Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CR8020, a Monoclonal Antibody Against Influenza A Viruses, Following Single-Dose and Repeat-Dose Intravenous Administration
Status: Enrolling
Updated: 7/16/2013
Quintiles Early Clinical Development
mi
from
Overland Park, KA
Click here to add this to my saved trials
Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014
Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014
Status: Enrolling
Updated:  8/1/2013
Centers for Disease Control and Prevention
mi
from
Atlanta, GA
Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014
Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014
Status: Enrolling
Updated: 8/1/2013
Centers for Disease Control and Prevention
mi
from
Atlanta, GA
Click here to add this to my saved trials
Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014
Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014
Status: Enrolling
Updated:  8/1/2013
Columbia University
mi
from
New York, NY
Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014
Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014
Status: Enrolling
Updated: 8/1/2013
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
PET-CT Scans in Healthy Volunteers After Flu Vaccination
Impact of Bilateral Priming on Response to Unilateral Flu Vaccination
Status: Enrolling
Updated:  8/26/2013
Hackensack Univarsity medical Center
mi
from
Hackensack, NJ
PET-CT Scans in Healthy Volunteers After Flu Vaccination
Impact of Bilateral Priming on Response to Unilateral Flu Vaccination
Status: Enrolling
Updated: 8/26/2013
Hackensack Univarsity medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years
Status: Enrolling
Updated:  8/26/2013
Accelovance, Inc.
mi
from
San Diego, CA
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years
Status: Enrolling
Updated: 8/26/2013
Accelovance, Inc.
mi
from
San Diego, CA
Click here to add this to my saved trials
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years
Status: Enrolling
Updated:  8/26/2013
Accelovance
mi
from
Melbourne, FL
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years
Status: Enrolling
Updated: 8/26/2013
Accelovance
mi
from
Melbourne, FL
Click here to add this to my saved trials
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years
Status: Enrolling
Updated:  8/26/2013
Accelovance
mi
from
Peoria, IL
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years
Status: Enrolling
Updated: 8/26/2013
Accelovance
mi
from
Peoria, IL
Click here to add this to my saved trials
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years
Status: Enrolling
Updated:  8/26/2013
Accelovance
mi
from
Rockville, MD
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years
Status: Enrolling
Updated: 8/26/2013
Accelovance
mi
from
Rockville, MD
Click here to add this to my saved trials
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years
Status: Enrolling
Updated:  8/26/2013
Site 05: Janet Lewis
mi
from
Salt Lake City, UT
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years
Status: Enrolling
Updated: 8/26/2013
Site 05: Janet Lewis
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years
Status: Enrolling
Updated:  8/26/2013
Site 06: Janet Lewis
mi
from
Salt Lake City, UT
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years
Status: Enrolling
Updated: 8/26/2013
Site 06: Janet Lewis
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy
A Randomized Pilot Study Comparing High-Dose Influenza Vaccine to Standard-Dose Influenza Vaccine in Adult Oncology Patients Less Than 65 Years Receiving Chemotherapy
Status: Enrolling
Updated:  8/27/2013
Rochester General Hospital
mi
from
Rochester, NY
Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy
A Randomized Pilot Study Comparing High-Dose Influenza Vaccine to Standard-Dose Influenza Vaccine in Adult Oncology Patients Less Than 65 Years Receiving Chemotherapy
Status: Enrolling
Updated: 8/27/2013
Rochester General Hospital
mi
from
Rochester, NY
Click here to add this to my saved trials
Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy
A Randomized Pilot Study Comparing High-Dose Influenza Vaccine to Standard-Dose Influenza Vaccine in Adult Oncology Patients Less Than 65 Years Receiving Chemotherapy
Status: Enrolling
Updated:  8/27/2013
Lipson Cancer Center Linden Oaks Medical Campus
mi
from
Rochester, NY
Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy
A Randomized Pilot Study Comparing High-Dose Influenza Vaccine to Standard-Dose Influenza Vaccine in Adult Oncology Patients Less Than 65 Years Receiving Chemotherapy
Status: Enrolling
Updated: 8/27/2013
Lipson Cancer Center Linden Oaks Medical Campus
mi
from
Rochester, NY
Click here to add this to my saved trials